Dr. West on FDA Approval of Frontline Alectinib in ALK+ NSCLC

H. Jack West, MD
Published: Monday, Nov 06, 2017



H. Jack West, MD, a thoracic oncologist of Swedish Cancer Institute at Swedish Medical Center, discusses the FDA approval of alectinib (Alecensa) as a first-line treatment for patients with ALK-positive, metastatic non–small cell lung cancer (NSCLC).


H. Jack West, MD, a thoracic oncologist of Swedish Cancer Institute at Swedish Medical Center, discusses the FDA approval of alectinib (Alecensa) as a first-line treatment for patients with ALK-positive, metastatic non–small cell lung cancer (NSCLC).

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Oncology Best Practice™: Choosing Therapies for Patients with EGFR-mutant Lung Cancers: More Options... More Decisions... Better OutcomesApr 27, 20182.0
Community Practice Connections™: 21st Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and MyelomaApr 27, 20182.0
Publication Bottom Border
Border Publication
x